EUVIMEDEUVIMED entdecken
Crossref

Development of a Supermolecular Radionuclide-Drug Conjugate System for Integrated Radiotheranostics for Non-small Cell Lung Cancer

Xinmiao Lu iD, Yunyun Zhu, Xiaohui Deng, Fei Kong, Chuang Xi, Quanyong Luo, Xinyuan Zhu iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xinmiao Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200235, Chi…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radionuclide-drug conjugates (RDCs) designed from small molecule or nanoplatform shows complementary characteristics. We constructed a new RDC system with integrated merits of small molecule and nanoplatform-based RDCs. Erlotinib was labeled with 131I to construct the bulk of RDC (131I-ER). Floxuridine was mixed with 131I-ER to develop a hydrogen bond-driving supermolecular RDC system (131I-ER-Fu NPs). The carrier-free 131I-ER-Fu NPs supermolecule not only demonstrated integrated merits of small molecule and nanoplatform-based RDC, including clear structure definition, stable quality control, prolonged circulation lifetime, enhanced tumor specificity and retention, and rapidly nontarget clearance, but also exhibited low biological toxicity and stronger antitumor effects. In vivo imaging also revealed its application for tumor localization of nonsmall cell lung cancer (NSCLC) and screening of patients suitable for epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. We considered that 131I-ER-Fu NPs showed potentials as an integrated platform for the radiotheranostics of NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansAnimalsMiceFloxuridineIodine RadioisotopesErlotinib HydrochlorideAntineoplastic AgentsRadiopharmaceuticalsCell Line, TumorTissue DistributionMice, NudeErbB ReceptorsMice, Inbred BALB CFemale

Substanzen

FloxuridineIodine RadioisotopesErlotinib HydrochlorideAntineoplastic AgentsRadiopharmaceuticalsErbB Receptors

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200235, China.
  • School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.

ORCID-Profile: Xinmiao Lu, Xinyuan Zhu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lu, X., Zhu, Y., Deng, X., Kong, F., Xi, C., Luo, Q., & Zhu, X. (2024). Development of a Supermolecular Radionuclide-Drug Conjugate System for Integrated Radiotheranostics for Non-small Cell Lung Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00673

Vancouver

Lu X, Zhu Y, Deng X, Kong F, Xi C, Luo Q, et al. Development of a Supermolecular Radionuclide-Drug Conjugate System for Integrated Radiotheranostics for Non-small Cell Lung Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00673

BibTeX
@article{Lu2024,
  author = {Lu, Xinmiao and Zhu, Yunyun and Deng, Xiaohui and Kong, Fei and Xi, Chuang and Luo, Quanyong and Zhu, Xinyuan},
  title = {Development of a Supermolecular Radionuclide-Drug Conjugate System for Integrated Radiotheranostics for Non-small Cell Lung Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00673}
}
Kostenlos starten →